Accuray Inc. offered a classic good news-bad news set-up for investors on Wednesday, with a notable FDA 510(k) clearance balanced by a miss on fourth quarter revenue and projections for fiscal year 2024 significantly below consensus expectations. Still, the takeaway is generally positive, with several strong catalysts expected to build momentum for the company in the coming year and much of the underperformance attributable to foreign exchange headwinds that have plagued many med-tech companies.
Beigene Co. Ltd. has divulged antibody-drug conjugates (ADC) comprising HER3 (erbB3) targeting antibody linked to an effector molecule through a linker reported to be useful for the treatment of cancer, metabolic diseases, neurodegeneration and inflammation.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has identified immunostimulatory antibody-drug conjugates (ISAC) comprising immunomodulators (Toll-like receptor 7 [TLR7] and/or TLR8 agonists) bound to antibodies through cleavable or uncleavable linkers reported to be useful for the treatment of cancer.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceuticals Co. Ltd. have disclosed antibody-drug conjugates (ADC) comprising human monoclonal antibodies targeting ROR1 covalently linked to exatecan through a linker. They are reported to be useful for the treatment of cancer.
Circle Pharma Inc. has selected CID-078 as its first clinical development candidate. CID-078 is an orally bioavailable macrocycle with dual cyclin A and B inhibitory activity that drives synthetic lethality in multiple tumor types.
Researchers from the U.S. National Cancer Institute and collaborators had previously demonstrated the therapeutic efficacy of an autologous whole tumor cell vaccine, named rWTC-MBTA, to prevent primary tumor growth and enhance mouse survival in a colon carcinoma model. The vaccine is composed of irradiated entire tumor cells (rWTC) pulsed with mannan-BAM (a pathogen-associated molecular pattern), TLR agonists and anti-CD40 antibody (MBTA).
Kelun-Biotech Biopharmaceutical Co. Ltd. raised HK$1.36 billion (US$174 million) in an IPO in Hong Kong to support its push into the increasingly competitive antibody-drug conjugate (ADC) market in China.
Nanjing Zenshine Pharmaceuticals Co. Ltd. has disclosed fused heterocyclic compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
B7-H4 is an immune-suppressive protein overexpressed in several tumors, including breast, endometrial and ovarian cancers, that has been successfully targeted with antibody-drug conjugate (ADC) strategies in preclinical testing.
